- names:
Peptide T
- CAS號(hào):
106362-32-7
MDL Number: - MF(分子式): C35H55N9O16 MW(分子量): 857.86
- EINECS: Reaxys Number:
- Pubchem ID:73352 Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (¥) | 現(xiàn)價(jià)(¥) | 特價(jià)(¥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000698-5mg | 5mg | >97%hc | ¥ 2936.00 | ¥ 2936.00 | Backorder | ¥ 0.00 | ||
| YZM000698-1mg | 1mg | >97%hc | ¥ 675.00 | ¥ 675.00 | 1-3天 | ¥ 0.00 |
- 大包裝詢價(jià) 提供各種包裝,敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車 立即購(gòu)買
| 中文別名 | 肽T(106362-32-7);HIV肽T;肽T;肽T,HIV;H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-OH; L-丙氨酰-L-絲氨酰-L-蘇氨酸-L-蘇氨酸-L-蘇氨酸-L-天冬酰胺-L-酪氨酰-L-蘇氨酸; (2S,3R)-2-[[(2S)-2-[[(2S)-4-氨基-2-[[(2S,3R)-2-[[(2S,3R)-2-[[ (2S,3R)-2-[[((2S)-2-[[(2S)-2-氨基丙?;鵠氨基] -3-羥基丙?;鵠氨基] -3-羥基丁?;鵠氨基] -3-羥基丁酰基]氨基]- 3-羥基丁?;鵠氨基] -4-氧丁?;鵠氨基] -3-(4-羥基苯基)丙?;鵠氨基] -3-羥基丁酸;HIV肽T; 肽T; 肽T,HIV; |
| 英文別名 | Peptide T(106362-32-7);HIV Peptide T;Peptide T;Peptide T, HIV; H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-OH; L-alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparagyl-L-tyrosyl-L-threonine; (2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid; HIV Peptide T; Peptide T; Peptide T, HIV; |
| CAS號(hào) | 106362-32-7 |
| Inchi | 1S/C35H55N9O16/c1-13(36)28(52)40-22(12-45)31(55)41-25(15(3)47)33(57)43-26(16(4)48)34(58)42-24(14(2)46)32(56)39-21(11-23(37)51)29(53)38-20(10-18-6-8-19(50)9-7-18)30(54)44-27(17(5)49)35(59)60/h6-9,13-17,20-22,24-27,45-50H,10-12,36H2,1-5H3,(H2,37,51)(H,38,53)(H,39,56)(H,40,52)(H,41,55)(H,42,58)(H,43,57)(H,44,54)(H,59,60)/t13-,14+,15+,16+,17+,20-,21-,22-,24-,25-,26-,27-/m0/s1 |
| InchiKey | IWHCAJPPWOMXNW-LYKMMFCUSA-N |
| 分子式 Formula | C35H55N9O16 |
| 分子量 Molecular Weight | 857.86 |
| 溶解度Solubility | |
| 性狀 | Solid |
| 儲(chǔ)藏條件 Storage conditions | 存放在陰涼干燥處 |
肽T(Peptide T,106362-32-7)實(shí)驗(yàn)注意事項(xiàng):
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡,穿戴防護(hù)服和口罩,佩戴手套,避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ),并交于專業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:肽T試劑,肽T雜質(zhì),肽T中間體,肽T密度,肽T旋光度,肽T溶解度,肽T閃點(diǎn),肽T結(jié)構(gòu)式,肽T購(gòu)買,肽T熔點(diǎn),
| 產(chǎn)品說明 | 肽T(Peptide T,106362-32-7)是源自HIV-1 gp120的V2區(qū)的八肽 |
| Introduction | 肽T(Peptide T,106362-32-7) is an octapeptide from the V2 region of HIV gp120. Peptide T is a ligand for theCD4receptor and prevents binding of HIVto the CD4 receptor. |
| Application1 | Peptide T是源自HIV-1 gp120的V2區(qū)的八肽。 Peptide T是 CD4 受體的配體,可阻止 HIV 與CD4受體結(jié)合。 |
| Application2 | |
| Application3 |
肽T(Peptide T,106362-32-7)藥理學(xué):
肽T是一種HIV進(jìn)入抑制劑,它通過阻斷趨化因子5受體(CCR5)發(fā)揮作用,目前正在臨床試驗(yàn)中,用于治療HIV相關(guān)的神經(jīng)和體質(zhì)癥狀。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡(如果有)并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過程中防止吸入、食入,做好安全防護(hù) |
| 1.Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2(8561):751. |
| 2.Ruff MR, et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63-75. |
| 3.Raychaudhuri SP, et al. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol. 1999 Sep;21(9):609-15. |
| 4.Sáez-Torres I, et al. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000 Jul;121(1):151-6. |
| 5Syntheses of mucin-type O-glycopeptides and oligosaccharides using transglycosylation and reverse-hydrolysis activities of Bifidobacterium endo-α-N-acetylgalactosaminidase Glycoconjugate Journal 2009 |
肽T(Peptide T,106362-32-7)參考文獻(xiàn):
1.Phosphoenolpyruvate-dependent phosphotransferase system of Staphylococcus aureus: factor IIIlac, a trimeric phospho-carrier protein that also acts as a phase transfer catalyst.
Deutscher J;Beyreuther K;Sobek HM;Stüber K;Hengstenberg W Biochemistry. 1982 Sep 28;21(20):4867-73.
Factor IIIlac (FIII) consists of three identical subunits. It could be shown that each of the subunits carries a phosphoryl group upon phosphorylation (P-FIII) with phosphoenolpyruvate (PEP), enzyme I, and histidine-containing phospho-carrier protein (HPr). The phosphoryl group is bound to a histidyl residue in P-FIII. Each subunit of FIII contains four histidyl residues. After tryptic cleavage a peptide was isolated that contained one other histidyl residue besides the active center histidine. By further cleavage of the peptide T-2 with V-8 Staphylococcus aureus protease it could be shown that His-19 in the sequence of the peptide T-2 is the active center histidine. Another peptide (1-38), caused by incomplete tryptic cleavage, could be isolated. It inhibited the phospho-transfer reaction from PEP to the sugar molecule at the step of factor III-enzyme II recognition. It competes with factor III for the binding site of enzyme II, the membrane component. It is a very hydrophobic peptide. This hydrophobic region is buried in factor III. But upon phosphorylation of factor III it is turned out. Thus P-FIII binds to Triton X-100 micelles whereas factor III does not. This conformational change caused by phosphorylation could be shown by proton nuclear magnetic resonance methods [Kalbitzer, H.
2.Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
Heseltine PN;Goodkin K;Atkinson JH;Vitiello B;Rochon J;Heaton RK;Eaton EM;Wilkie FL;Sobel E;Brown SJ;Feaster D;Schneider L;Goldschmidts WL;Stover ES Arch Neurol. 1998 Jan;55(1):41-51.
BACKGROUND: ;Cognitive impairment is a common consequence of human immunodeficiency virus (HIV) infection, and dementia is one of the diseases that defines the acquired immunodeficiency syndrome. Peptide T (d-ala-peptide-T-amide) has been reported to block the binding of gp120 to brain tissue and to protect neurons from the toxic effects of gp120 in vitro. In pilot studies, administration of peptide T to HIV-positive patients with cognitive impairment was associated with improvement in cognition and constitutional symptoms.;OBJECTIVE: ;To determine whether the intranasal administration of peptide T would improve cognitive function of HIV-positive patients with cognitive impairment.;PATIENTS AND METHODS: ;This was a 3-site, double-blind, placebo-controlled trial of peptide T given intranasally at a dosage of 2 mg 3 times a day for 6 months. Participants were HIV-seropositive persons with evidence of cognitive deficits on a screening test battery. Concomitant antiretroviral therapy was allowed. Randomization to the 2 study arms was balanced according to several stratification variables, such as CD4+ cell count, severity of cognitive impairment, and antiretroviral therapy at study entry.
3.A 500 MHz study of peptide T in a DMSO solution.
Picone D;Temussi PA;Marastoni M;Tomatis R;Motta A FEBS Lett. 1988 Apr 11;231(1):159-63.
Peptide T, an octapeptide of sequence ASTTTNYT that binds to human T cells, was studied as a zwitterion in DMSOd6 solution by means of proton NMR spectroscopy at 500 MHz. The unusual dispersion of the resonances of residues of the same type (T) makes it possible to assign all resonances to specific residues by means of several 2D techniques. The non-random nature of the conformation is substantiated by the observation of sequential nuclear Overhauser enhancements (NOEs). The low value of the temperature coefficient of the chemical shift of the NH of T8 and a diagnostic NOE between the NHs of T7 and T8 hint that a beta-turn including T5, N6, Y7 and T8 is a prominent conformational feature in solution. The ring current high field shifts of the methyl group and of the NH of T8 are consistent with an interaction with the side-chain of Y7, favoured by the beta-turn.
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色,是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長(zhǎng),主要用于組織學(xué),免疫組織化學(xué)...
2020/7/20 22:04:33

提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26

9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55

Waxfilm 實(shí)驗(yàn)室封口膜:技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域,封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來,Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40

Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07

各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09

新一代微流控鍵合解決方案
微流控鍵合解決方案:微流控芯片制造的一個(gè)重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是:微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說明
D-熒光素鉀鹽(K+)設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11

如何選BSA(牛血清白蛋白)
如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18

牛血清白蛋白(BSA)常見問題
牛血清白蛋白(BSA)常見問題:牛血清白蛋白(BSA)在實(shí)驗(yàn)室中是通用的,可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51



購(gòu)物車 


